{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:53:20Z","timestamp":1769252000283,"version":"3.49.0"},"reference-count":22,"publisher":"Medical Association of Nippon Medical School","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2023,2,25]]},"DOI":"10.1272\/jnms.jnms.2023_90-115","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T22:13:48Z","timestamp":1678486428000},"page":"96-102","source":"Crossref","is-referenced-by-count":2,"title":["Change in Antinuclear Antibody Titers during Biologic Treatment for Psoriasis"],"prefix":"10.1272","volume":"90","author":[{"given":"Shun","family":"Miyazaki","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ichiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hoashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kanda N, Hoashi T, Saeki H. Nutrition and psoriasis. Int J Mol Sci. 2020 Jul;21 (5):5405.","DOI":"10.3390\/ijms21155405"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kanda N, Hoashi T, Saeki H. The defect in regulatory T cells in psoriasis and therapeutic approaches. J Clin Med. 2021 Aug;10 (17):3880.","DOI":"10.3390\/jcm10173880"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020 Mar;47 (3):201-22.","DOI":"10.1111\/1346-8138.15196"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Debandt M, Vittecoq O, Descamps V, Le Lo\u00ebt X, Meyer O. Anti-TNF-\u03b1-induced systemic lupus syndrome. Clin Rheumatol. 2003 Feb;22 (1):56-61.","DOI":"10.1007\/s10067-002-0654-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. De Bandt M, Sibilia J, Le Lo\u00ebt X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7 (3):R545-51.","DOI":"10.1186\/ar1715"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ozaki S, Ichiyama S, Ito M, Hoashi T, Kanda N, Saeki H. Real-world blood examination screening data before initiation of biologics for psoriasis patients. J Dermatol. 2022;49 (5):534-8.","DOI":"10.1111\/1346-8138.16333"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Poulalhon N, Begon E, Lebb\u00e9 C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007 Feb;156 (2):329-36.","DOI":"10.1111\/j.1365-2133.2006.07639.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Pink AE, Fonia A, Allen MH, Smith CH, Barker JNWN. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-\u03b1 therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010 Apr;162 (4):780-5.","DOI":"10.1111\/j.1365-2133.2009.09563.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Saracemo R, Speccbio F, Torres T, Nistico SP, Rizza S, Chimenti S. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study. J Am Acad Dermatol. 2010 May;66 (5):e180-2.","DOI":"10.1016\/j.jaad.2011.06.008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chimenti MS, Spinelli FR, Giunta A, et al. Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review. Drug Dev Res. 2014 Nov;75 (Supple 1):S61-3.","DOI":"10.1002\/ddr.21198"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bardazzi F, Odorici G, Virdi A, et al. Autoantibodies in psoriatic patients treated with anti-TNF-\u03b1 therapy. J Dtsch Dermatol Ges. 2014 May;12 (5):401-6.","DOI":"10.1111\/ddg.12339"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takase K, Horton SC, Ganesha A, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis. 2014 Sep;73 (9):1695-9.","DOI":"10.1136\/annrheumdis-2014-205318"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pirowska MM, Go\u017adzialska A, Lipko-Godlewska S, et al. Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis. Postepy Dermatol Alergol. 2015 Aug;32 (4):250-4.","DOI":"10.5114\/pdia.2015.53320"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oter-L\u00f3pez B, Llamas-Velasco M, S\u00e1nchez-P\u00e9rez J, Dauden E. Induction of autoantibodies and autoimmune diseases in patients with psoriasis receiving tumor necrosis factor inhibitors. Actas Dermosifiliogr. 2017 Jun;108 (5):445-56.","DOI":"10.1016\/j.adengl.2017.03.031"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yanaba K, Umezawa Y, Honda H, et al. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis. J Dermatol. 2016 Apr;43 (4):443-4.","DOI":"10.1111\/1346-8138.13215"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rodr\u00edguez-Jim\u00e9nez P, Chicharro P, Godoy A, Llamas-Velasco M, Garc\u00eda M, Daud\u00e9n E. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab. Br J Dermatol. 2017 Sep;177 (3):862-3.","DOI":"10.1111\/bjd.15654"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Miki M, Endo C, Naka Y, et al. Increase in antinuclear antibody levels through biologic treatment for psoriasis. J Dermatol. 2019 Feb;46 (2):e50-1.","DOI":"10.1111\/1346-8138.14578"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kutlu \u00d6, \u00c7etinkaya P, \u015eahin T, Ek\u015fio\u011flu HM. The effect of biological agents on antinuclear antibody status in patients with psoriasis: a single-center study. Indian Dermatol Online J. 2020 Nov;11 (6):904-9.","DOI":"10.4103\/idoj.IDOJ_164_20"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sugiura R, Terui H, Shimada-Omori R, et al. Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients. J Dermatol. 2021 Nov;48 (11):1739-44.","DOI":"10.1111\/1346-8138.16102"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157 (4):238-44.","DOI":"10.1159\/000250839"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Almoallim H, Al-Ghamdi Y, Almaghradi H, Alyasi O. Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus. Open Rheumatol J. 2012;6:315-9.","DOI":"10.2174\/1874312901206010315"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999 Jun;5 (6):694-7.","DOI":"10.1038\/9544"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/1\/90_JNMS.2023_90-115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:08:08Z","timestamp":1678507688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/1\/90_JNMS.2023_90-115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2023_90-115","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"article-number":"JNMS.2023_90-115"}}